{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone+45+mg&page=3", "query": { "intervention": "Pioglitazone 45 mg", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 91, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone+45+mg&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pioglitazone+45+mg&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T14:20:54.453Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00545233", "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2008-01", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-05-07", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545233" }, { "nct_id": "NCT00634036", "title": "Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "pioglitazone", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fernando Holguin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 23, "start_date": "2009-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Colchester, Vermont", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Colchester", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634036" }, { "nct_id": "NCT00376181", "title": "Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Pioglitazone and Azilsartan", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2006-06", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2010-06-22", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 59, "location_summary": "Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tallassee", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376181" }, { "nct_id": "NCT00443755", "title": "Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes", "Insulin Resistance", "Metabolic Syndrome" ], "interventions": [ { "name": "metformin", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 28, "start_date": "2005-08", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2013-10-31", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00443755" }, { "nct_id": "NCT01183013", "title": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Pioglitazone 45 mg", "type": "DRUG" }, { "name": "Pioglitazone 30 mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 45 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 30 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 15 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 936, "start_date": "2010-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183013" }, { "nct_id": "NCT01103414", "title": "Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Mitoglitazone", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Metabolic Solutions Development Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 356, "start_date": "2010-09", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 24, "location_summary": "Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01103414" }, { "nct_id": "NCT00923949", "title": "Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New York, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923949" }, { "nct_id": "NCT01023620", "title": "HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2009-10", "completion_date": "2010-05-31", "has_results": true, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023620" }, { "nct_id": "NCT01280695", "title": "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "MSDC-0602 100 mg", "type": "DRUG" }, { "name": "MSDC-0602 250 mg", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Metabolic Solutions Development Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 129, "start_date": "2011-02", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2014-04-14", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 14, "location_summary": "Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01280695" }, { "nct_id": "NCT00816218", "title": "Molecular Mechanisms of Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2003-03", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2012-05-31", "last_synced_at": "2026-10-06T14:20:54.453Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00816218" } ] }